Your browser doesn't support javascript.
loading
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial.
Rannikko, Jenna H; Verlingue, Loic; de Miguel, Maria; Pasanen, Annika; Robbrecht, Debbie; Skytta, Tanja; Iivanainen, Sanna; Shetty, Shishir; Ma, Yuk Ting; Graham, Donna M; Arora, Sukeshi Patel; Jaakkola, Panu; Yap, Christina; Xiang, Yujuan; Mandelin, Jami; Karvonen, Matti K; Jalkanen, Juho; Karaman, Sinem; Koivunen, Jussi P; Minchom, Anna; Hollmén, Maija; Bono, Petri.
Afiliação
  • Rannikko JH; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland; Turku Doctoral Program of Molecular Medicine, University of Turku, Turku, Finland.
  • Verlingue L; Institut Gustave Roussy, Paris and Centre Leon Berard in Lyon, Lyon, France.
  • de Miguel M; START-CIOCC HM Sanchinarro, Madrid, Spain.
  • Pasanen A; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Robbrecht D; Erasmus Medical Center/Cancer Institute, Rotterdam, the Netherlands.
  • Skytta T; Tampere University Hospital, Tampere, Finland.
  • Iivanainen S; Oulu University Hospital, University of Oulu, Oulu, Finland.
  • Shetty S; University of Birmingham/University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Ma YT; University of Birmingham/University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Graham DM; The Christie NHS Foundation Trust, Manchester, UK.
  • Arora SP; Mays Cancer Center, UT Health San Antonio, San Antonio, TX, USA.
  • Jaakkola P; Department of Oncology, Turku University Hospital and University of Turku, Turku, Finland.
  • Yap C; Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK.
  • Xiang Y; INDIVIDRUG Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Mandelin J; Faron Pharmaceuticals Ltd, Turku, Finland.
  • Karvonen MK; Faron Pharmaceuticals Ltd, Turku, Finland.
  • Jalkanen J; Faron Pharmaceuticals Ltd, Turku, Finland.
  • Karaman S; INDIVIDRUG Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Wihuri Research Institute, Helsinki, Finland.
  • Koivunen JP; Oulu University Hospital, University of Oulu, Oulu, Finland; Faron Pharmaceuticals Ltd, Turku, Finland.
  • Minchom A; Drug Development Unit, Royal Marsden Hospital/Institute of Cancer Research, Sutton, UK.
  • Hollmén M; MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland; Faron Pharmaceuticals Ltd, Turku, Finland. Electronic address: maijal@utu.fi.
  • Bono P; Terveystalo Finland and University of Helsinki, Helsinki, Finland. Electronic address: petri.bono@terveystalo.com.
Cell Rep Med ; 4(12): 101307, 2023 12 19.
Article em En | MEDLINE | ID: mdl-38056464
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Monoclonais Humanizados / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article